Overview

Open-Trial of EPI-743 for Adults With Tourette Syndrome

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effects of EPI-743 on tic severity in adults with Tourette syndrome.
Phase:
Phase 1
Details
Lead Sponsor:
Yale University
Collaborators:
Edison Pharmaceuticals Inc
Rembrandt Foundation
Treatments:
Ubiquinone